Concepedia
Statistics
Publications
21
Citations
2K
H-Index
15
Active since
2009
Affiliations
Fudan University Shanghai Cancer Center(Current)
Peking University
Institute of Hematology & Blood Diseases Hospital
Chinese Academy of Medical Sciences & Peking Union Medical College
Peking University Cancer Hospital
Haiyi Guo is an author at Fudan University Shanghai Cancer Center specializing in medicine, pharmacology, and oncology.
Publications per year
2009–2024
YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity <i>in vitro</i> and <i>in vivo</i>
Shu Tian, Haitian Quan, Chengying Xie et al. · Cancer Science · 2011 · 521 citations · Full text
Medicine, Oncology, Pharmacology +17
Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies
Li Jin, Xinmin Zhao, Lei Chen et al. · BMC Cancer · 2010 · 274 citations · Full text
Pharmacy, Oncology, Pharmacology +15
Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
Yuqin Song, Keshu Zhou, Dehui Zou et al. · Clinical Cancer Research · 2020 · 183 citations
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
Yuqin Song, Keshu Zhou, Dehui Zou et al. · Blood · 2022 · 169 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +16
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
Yuqin Song, Quanli Gao, Huilai Zhang et al. · Leukemia · 2019 · 157 citations · Full text
Medicine, Oncology, Pharmacotherapy +17
1–5 of 21